Efficacy and safety of PF-00299804 (PF299) in patients (pt) with advanced NSCLC after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib (E): A two-arm, phase II trial.

@article{Janne2009EfficacyAS,
  title={Efficacy and safety of PF-00299804 (PF299) in patients (pt) with advanced NSCLC after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib (E): A two-arm, phase II trial.},
  author={Pasi Antero Janne and Karen L Reckamp and Marianna N Koczywas and Jeffrey A. Engelman and David Ross Camidge and Arun Rajan and Fadlo R. Khuri and Jane Q Liang and Joseph O'Connell and Guiseppe Giaccone},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2009},
  volume={27 15_suppl},
  pages={8063}
}
8063 Background: Options are limited for pts with NSCLC following chemotherapy and E. PF299 is an oral irreversible small molecule inhibitor of the HER-1,-2, and -4 tyrosine kinases. Based on non-clinical and phase I NSCLC data, this ongoing phase II U.S. trial evaluates PF299 in pts with NSCLC (KRAS wild-type) who have progressive disease after at least 1 prior chemotherapy regimen and after E. METHODS Pts were enrolled by histology: adenocarcinoma (Arm A) and non-adenocarcinoma (Arm B), and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

Similar Papers

Loading similar papers…